NASDAQ:RCM - R1 RCM Stock Price, Forecast & News

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

R1 RCM Inc (NASDAQ:RCM) released its quarterly earnings data on Thursday, February, 20th. The healthcare provider reported $0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by $0.03. The healthcare provider earned $314 million during the quarter, compared to analysts' expectations of $318.36 million. R1 RCM had a net margin of 1.01% and a return on equity of 116.79%. R1 RCM's revenue was up 19.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.10) EPS. View R1 RCM's Earnings History.

R1 RCM is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for R1 RCM.

R1 RCM updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.3-1.4 billion, compared to the consensus revenue estimate of $1.36 billion.

4 equities research analysts have issued 1 year target prices for R1 RCM's shares. Their forecasts range from $14.00 to $17.00. On average, they expect R1 RCM's share price to reach $15.25 in the next year. This suggests a possible upside of 17.0% from the stock's current price. View Analyst Price Targets for R1 RCM.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for R1 RCM.

News headlines about RCM stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. R1 RCM earned a news impact score of -3.0 on InfoTrie's scale. They also gave news coverage about the healthcare provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for R1 RCM.

R1 RCM saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 7,780,000 shares, an increase of 17.3% from the December 31st total of 6,630,000 shares. Based on an average daily trading volume, of 1,160,000 shares, the days-to-cover ratio is presently 6.7 days. Approximately 8.0% of the shares of the stock are short sold. View R1 RCM's Current Options Chain.

Some companies that are related to R1 RCM include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), BioScrip (BIOS), Davita (DVA), Chemed (CHE), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include Alibaba Group (BABA), NVIDIA (NVDA), Baozun (BZUN), Marvell Technology Group (MRVL), Baidu (BIDU), JD.Com (JD), Canopy Growth (CGC), Model N (MODN), Advanced Micro Devices (AMD) and BioDelivery Sciences International (BDSI).

R1 RCM's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (2.27%), State Street Corp (2.00%), Bank of New York Mellon Corp (1.92%), Geode Capital Management LLC (1.24%), Royce & Associates LP (1.15%) and Eaton Vance Management (1.14%). Company insiders that own R1 RCM stock include Albert Rene Zimmerli and Charles J Ditkoff. View Institutional Ownership Trends for R1 RCM.

RCM stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Renaissance Technologies LLC, Penn Capital Management Co. Inc., Falcon Point Capital LLC, Point72 Asset Management L.P., Castleark Management LLC, PNC Financial Services Group Inc. and Prudential Financial Inc.. View Insider Buying and Selling for R1 RCM.

RCM stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Mckinley Capital Management LLC Delaware, Eaton Vance Management, Eagle Asset Management Inc., Tealwood Asset Management Inc., Parkman Healthcare Partners LLC, Bank of Montreal Can and Sectoral Asset Management Inc. View Insider Buying and Selling for R1 RCM.

Shares of RCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RCM stock can currently be purchased for approximately $13.03.

R1 RCM has a market capitalization of $1.47 billion and generates $1.19 billion in revenue each year. R1 RCM employs 18,600 workers across the globe.View Additional Information About R1 RCM.

The official website for R1 RCM is http://www.r1rcm.com/.

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider can be reached via phone at 312-324-7820 or via email at [email protected]